SCHEMBL13699145

SCHEMBL13699145

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CC5CCC(C4)N5C)cc3)cc2)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 0.43
RAF1 P04049 5/20 0.43
KDR P35968 2/20 0.40
BRAF P15056 2/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
PKM P14618 1/20 0.39
FGFR1 P11362 1/20 0.38
ARAF P10398 1/20 0.38
FAAH O00519 2/20 0.38
SRC P12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699147 0.90 PKM (0.41) EPHX2KDRBRAFPKM
SCHEMBL13699163 0.89 PKM (0.41) EPHX2MEN1MAPTKMT2APKM
SCHEMBL13699285 0.89 PKM (0.41) EPHX2MEN1MAPTKMT2APKM
SCHEMBL13699155 0.89 PKM (0.41) MEN1CYP2D6KMT2APKM
SCHEMBL13699277 0.88 PKM (0.45) MEN1CYP2D6MAPTHTTKMT2A
SCHEMBL13699146 0.88 PNLIP (0.45) MEN1MAPTKMT2APKM
SCHEMBL13699204 0.88 PKM (0.48) EPHX2RAF1MEN1CYP2C9CYP2C19
SCHEMBL13699150 0.88 PKM (0.40) KDM4EMEN1MAPTKMT2APKM
SCHEMBL13699250 0.87 PKM (0.42) MEN1CYP2D6MAPTCYP2C9KMT2A
SCHEMBL4234052 0.87 EPHX2 (0.43) EPHX2RAF1KDRBRAFUBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R EPHX2 1515/4885RAF1 2279/4885KDR 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.